Overview

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Status:
Active, not recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurrence of ROP in the study and to assess the safety and tolerability of aflibercept.

Phase:

Phase 3

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Treatments:

Aflibercept